US Patent Litigations are now available. Check here

IP Verse

Astrazeneca patent opposition analysis

Latest patents of Astrazeneca opposed by its competitors

Explore Astrazeneca's recently opposed patents, revealing key competitive challenges and strategic patent disputes in the industry. Track oppositions filed by competitors to understand technology battlegrounds and assess potential risks.

Last updated on: Jul 3, 2025
Patent NumberGrant DateTitleTotal Oppositions
EP3045466Oct 16, 2024(2S,3R,4S,5S,6R)-2-[4-Chloro-3-(4-Ethoxy-Benzyl)-Phenyl]-6-Hydroxymethyl-2-Methoxy-Tetrahydro-Pyran-3,4,5-Triol Propylene Glycol Solvate As Sgt2 Inhibitor For The Treatment Of Diabetes1
EP4175619Apr 10, 2024Compositions, Methods And Systems For Aerosol Drug Delivery2
EP4175620Apr 10, 2024Compositions, Methods And Systems For Aerosol Drug Delivery1
EP4197528Apr 3, 2024Compositions, Methods And Systems For Aerosol Drug Delivery1
EP2341905Sep 13, 2023Sustained Release Formulations Using Non-Aqueous Carriers1
EP4114465Aug 30, 2023Anti-Ifnar1 Dosing Regime For Subcutaneous Injection1
EP2508188May 10, 2023Pharmaceutical Formulations Containing Dapagliflozin Propylene Glycol Hydrate5
EP3769781Apr 19, 2023Stable Anti-Ifnar1 Formulation1
EP2785349Nov 9, 2022Combination Treatment Of Cancer1
EP3142661Oct 6, 2021Method For Suppressing Glucagon Secretion Of An Sglt2 Inhibitor1

Top competitors of Astrazeneca